William Ulmer
Urology · Albany, NYNPI 1528327582
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,139 and has fallen 98.3% since, to $20 in 2024.
Across 218 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$822
- Astellas Pharma US Inc$716
- Dendreon Pharmaceuticals LLC$715
- Myovant Sciences Inc.$180
- Tolmar Pharmaceuticals, Inc.$164
- Blue Earth Diagnostics$163
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,09592%
- Education$3418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $822 |
| Astellas Pharma US Inc | 29 | $716 |
| Dendreon Pharmaceuticals LLC | 29 | $715 |
| Myovant Sciences Inc. | 12 | $180 |
| Tolmar Pharmaceuticals, Inc. | 9 | $164 |
| Blue Earth Diagnostics | 8 | $163 |
| Pfizer | 8 | $162 |
| Amgen | 9 | $145 |
| Merck | 7 | $130 |
| Endo Pharmaceuticals Inc. | 8 | $129 |
| Bayer | 7 | $122 |
| Boston Scientific | 4 | $120 |
| Teleflex LLC | 6 | $104 |
| Sumitomo Pharma America, Inc. | 4 | $90 |
| Urogen Pharma, Inc. | 3 | $75 |
| Ferring Pharmaceuticals Inc. | 5 | $73 |
| Myriad Genetic Laboratories, Inc. | 4 | $64 |
| Verity Pharmaceuticals Inc. | 3 | $60 |
| Neotract Inc. | 4 | $60 |
| Acerus Pharmaceuticals Corporation | 4 | $54 |
| Aytu Biopharma, Inc. | 4 | $52 |
| Progenics Pharmaceuticals, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Laborie Medical Technologies Corp. | 2 | $25 |
| Sanofi | 1 | $24 |
| AbbVie | 1 | $23 |
| 180 Medical, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Coloplast | 1 | $18 |
| Dentsply IH Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Accord Healthcare, Inc. | 1 | $15 |
How this compares
$4,436 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 20 | $232 |
Paid to pharmacies, not to this prescriber.
Other urology in Albany
- Ronald KaufmanAlbany$173K
- Brian MurrayAlbany$130K
- Brian InouyeAlbany$57K
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.